Feb 27 (Reuters) - U.S. and Liberian researchers have started a clinical trial to test the safety and effectiveness of Mapp Biopharmaceutical Inc's Ebola drug ZMapp, an experimental treatment that has already been tried in a handful of Ebola patients
Allergan AGN announced it intends to acquire MAP Pharmaceuticals for approximately $950 million. The news is not particularly surprising because both companies formed a partnership in 2011 for
(Reuters) - Shares of MAP Pharmaceuticals Inc fell by a third in premarket trade on Tuesday, after health regulators rejected its orally inhaled treatment for migraine, but analysts remain...
We are no longer providing equity research on MAP Pharmaceuticals MAPP . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
the projected in-service date for the MAPP transmission project by four to six years ..... be the best-case scenario. Given that MAPP promises 12.8% federally approved returns ..... violations earlier than 2019, making the MAPP transmission project unnecessary at this
insensitive to decreased customer usage from unfavorable weather, a poor economy, or energy efficiency improvements. If the high-returning MAPP transmission project ever gets off the ground, then overall returns should improve moderately.
Supply business. Weather had a negligible impact on results, since 64% of distribution revenue is decoupled from usage. Later this month, we expect PJM to push out the timing of its lucrative MAPP transmission project by at least six months.
procedure will result in gradual adoption over time. Allergan's recent joint-venture announcement with MAP Pharmaceuticals MAPP to market Levadex now makes Allergan one of the few firms marketing branded products to headache specialists
MAP Pharmaceuticals MAPP announced Monday it will partner with Allergan AGN to copromote MAP's lead drug candidate Levadex, its inhaled therapy for migraine
savings for Maryland customers as a result of the project, all of which is lost margin for area merchant generators. Aside from MAPP , we are more skeptical about the firm's investment plans, given mostly unfavorable regulatory action the past year. Management